| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Silymarin | 105 | 2017 | 199 | 21.540 |
Why?
|
| Prostatic Neoplasms | 93 | 2024 | 1016 | 13.450 |
Why?
|
| Chemical Warfare Agents | 25 | 2025 | 121 | 10.980 |
Why?
|
| Mustard Gas | 23 | 2025 | 110 | 9.470 |
Why?
|
| Apoptosis | 124 | 2023 | 2501 | 7.610 |
Why?
|
| Antineoplastic Agents, Phytogenic | 40 | 2019 | 187 | 7.290 |
Why?
|
| Mechlorethamine | 17 | 2024 | 63 | 6.840 |
Why?
|
| Corneal Injuries | 8 | 2024 | 50 | 6.110 |
Why?
|
| Skin | 31 | 2024 | 721 | 6.050 |
Why?
|
| Anticarcinogenic Agents | 25 | 2016 | 77 | 5.280 |
Why?
|
| Antioxidants | 38 | 2023 | 557 | 4.810 |
Why?
|
| Plant Extracts | 27 | 2020 | 194 | 4.780 |
Why?
|
| Cornea | 11 | 2024 | 128 | 4.360 |
Why?
|
| Cell Cycle | 40 | 2018 | 590 | 4.210 |
Why?
|
| Antineoplastic Agents | 39 | 2021 | 2058 | 3.940 |
Why?
|
| Ultraviolet Rays | 22 | 2022 | 382 | 3.880 |
Why?
|
| DNA Damage | 24 | 2019 | 384 | 3.850 |
Why?
|
| Cell Proliferation | 72 | 2021 | 2388 | 3.750 |
Why?
|
| Irritants | 13 | 2024 | 48 | 3.740 |
Why?
|
| Skin Neoplasms | 19 | 2022 | 823 | 3.550 |
Why?
|
| Neovascularization, Pathologic | 24 | 2018 | 297 | 3.290 |
Why?
|
| Adenocarcinoma | 18 | 2022 | 895 | 3.180 |
Why?
|
| Cell Line, Tumor | 84 | 2023 | 3211 | 3.020 |
Why?
|
| Animals | 164 | 2025 | 35219 | 2.980 |
Why?
|
| Phytic Acid | 11 | 2012 | 43 | 2.960 |
Why?
|
| Arsenicals | 5 | 2023 | 32 | 2.890 |
Why?
|
| Tumor Suppressor Protein p53 | 26 | 2019 | 511 | 2.770 |
Why?
|
| Carcinoma, Basal Cell | 5 | 2022 | 73 | 2.700 |
Why?
|
| Signal Transduction | 48 | 2020 | 4913 | 2.570 |
Why?
|
| NF-kappa B | 24 | 2016 | 653 | 2.560 |
Why?
|
| Mice | 114 | 2024 | 16861 | 2.530 |
Why?
|
| Cell Cycle Proteins | 22 | 2018 | 586 | 2.500 |
Why?
|
| Dexamethasone | 7 | 2025 | 346 | 2.450 |
Why?
|
| Nitric Oxide Synthase Type II | 16 | 2016 | 171 | 2.430 |
Why?
|
| Mice, Hairless | 27 | 2020 | 60 | 2.300 |
Why?
|
| Rabbits | 15 | 2025 | 778 | 2.300 |
Why?
|
| Momordica charantia | 4 | 2020 | 15 | 2.280 |
Why?
|
| Prostate | 13 | 2024 | 180 | 2.200 |
Why?
|
| Proto-Oncogene Proteins c-akt | 15 | 2018 | 431 | 2.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 15 | 2013 | 117 | 2.070 |
Why?
|
| Mice, Nude | 36 | 2020 | 683 | 2.070 |
Why?
|
| Cyclooxygenase 2 | 20 | 2021 | 177 | 2.010 |
Why?
|
| Anti-Inflammatory Agents | 6 | 2025 | 478 | 1.940 |
Why?
|
| Cell Survival | 32 | 2021 | 1085 | 1.930 |
Why?
|
| Vitis | 16 | 2013 | 41 | 1.930 |
Why?
|
| Colorectal Neoplasms | 15 | 2014 | 751 | 1.820 |
Why?
|
| Carcinoma | 9 | 2011 | 216 | 1.760 |
Why?
|
| Phytotherapy | 11 | 2012 | 79 | 1.750 |
Why?
|
| Oxidative Stress | 16 | 2025 | 1268 | 1.720 |
Why?
|
| MAP Kinase Signaling System | 10 | 2023 | 311 | 1.690 |
Why?
|
| Neoplasms | 17 | 2017 | 2467 | 1.690 |
Why?
|
| Xenograft Model Antitumor Assays | 26 | 2020 | 813 | 1.680 |
Why?
|
| Pancreatic Neoplasms | 6 | 2020 | 879 | 1.650 |
Why?
|
| Angiogenesis Inhibitors | 12 | 2019 | 219 | 1.600 |
Why?
|
| Dermatitis, Contact | 4 | 2013 | 17 | 1.590 |
Why?
|
| Vascular Endothelial Growth Factor A | 19 | 2019 | 527 | 1.570 |
Why?
|
| Protective Agents | 4 | 2017 | 38 | 1.560 |
Why?
|
| Mitogen-Activated Protein Kinases | 12 | 2020 | 312 | 1.540 |
Why?
|
| Male | 136 | 2025 | 63498 | 1.520 |
Why?
|
| Cadherins | 7 | 2018 | 188 | 1.510 |
Why?
|
| Lung Neoplasms | 16 | 2016 | 2339 | 1.500 |
Why?
|
| Eye Injuries | 3 | 2024 | 46 | 1.470 |
Why?
|
| Caspases | 17 | 2012 | 245 | 1.440 |
Why?
|
| Disease Models, Animal | 21 | 2024 | 4049 | 1.410 |
Why?
|
| Grape Seed Extract | 14 | 2019 | 44 | 1.400 |
Why?
|
| Humans | 199 | 2024 | 129219 | 1.390 |
Why?
|
| Dose-Response Relationship, Drug | 30 | 2021 | 2003 | 1.320 |
Why?
|
| Carcinogenesis | 7 | 2024 | 213 | 1.310 |
Why?
|
| Tumor Cells, Cultured | 30 | 2021 | 939 | 1.290 |
Why?
|
| Colonic Neoplasms | 10 | 2018 | 243 | 1.280 |
Why?
|
| Blister | 7 | 2017 | 41 | 1.280 |
Why?
|
| Gene Expression Regulation, Neoplastic | 20 | 2018 | 1354 | 1.280 |
Why?
|
| Enzyme Activation | 21 | 2020 | 811 | 1.260 |
Why?
|
| Epidermis | 6 | 2014 | 155 | 1.260 |
Why?
|
| Blotting, Western | 22 | 2016 | 1205 | 1.230 |
Why?
|
| Phosphorylation | 27 | 2019 | 1710 | 1.190 |
Why?
|
| Chemoprevention | 12 | 2019 | 90 | 1.190 |
Why?
|
| Transcription Factor AP-1 | 9 | 2016 | 85 | 1.180 |
Why?
|
| Neoplastic Stem Cells | 6 | 2019 | 380 | 1.180 |
Why?
|
| Corneal Neovascularization | 3 | 2017 | 15 | 1.170 |
Why?
|
| Immunohistochemistry | 22 | 2019 | 1696 | 1.160 |
Why?
|
| Skin Diseases | 4 | 2017 | 142 | 1.160 |
Why?
|
| Matrix Metalloproteinase 9 | 10 | 2021 | 119 | 1.160 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2020 | 755 | 1.150 |
Why?
|
| Keratinocytes | 5 | 2020 | 241 | 1.150 |
Why?
|
| Seeds | 14 | 2013 | 84 | 1.140 |
Why?
|
| Urinary Bladder Neoplasms | 6 | 2013 | 227 | 1.120 |
Why?
|
| Transcription Factors | 10 | 2014 | 1649 | 1.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 12 | 2012 | 73 | 1.100 |
Why?
|
| Caspase 3 | 12 | 2019 | 244 | 1.100 |
Why?
|
| Enzyme Inhibitors | 11 | 2013 | 826 | 1.090 |
Why?
|
| Transcriptional Regulator ERG | 2 | 2024 | 19 | 1.090 |
Why?
|
| DNA Repair | 6 | 2015 | 206 | 1.070 |
Why?
|
| Inflammation | 12 | 2025 | 2723 | 1.060 |
Why?
|
| Cell Movement | 12 | 2019 | 941 | 1.050 |
Why?
|
| STAT3 Transcription Factor | 9 | 2013 | 195 | 1.040 |
Why?
|
| Serine Endopeptidases | 2 | 2024 | 118 | 1.030 |
Why?
|
| Fibroblasts | 4 | 2016 | 944 | 1.000 |
Why?
|
| Antidotes | 5 | 2017 | 136 | 0.990 |
Why?
|
| Metabolomics | 5 | 2019 | 652 | 0.980 |
Why?
|
| Biomarkers | 6 | 2024 | 3968 | 0.970 |
Why?
|
| Neoplasm Invasiveness | 10 | 2020 | 481 | 0.970 |
Why?
|
| Microtubule-Associated Proteins | 8 | 2017 | 191 | 0.960 |
Why?
|
| Cell Division | 25 | 2015 | 796 | 0.950 |
Why?
|
| Limbus Corneae | 1 | 2025 | 9 | 0.950 |
Why?
|
| Down-Regulation | 14 | 2014 | 636 | 0.940 |
Why?
|
| Neoplasm Proteins | 9 | 2014 | 424 | 0.930 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2024 | 336 | 0.930 |
Why?
|
| Phosgene | 3 | 2024 | 7 | 0.920 |
Why?
|
| Hedgehog Proteins | 4 | 2022 | 188 | 0.910 |
Why?
|
| Epithelium, Corneal | 4 | 2019 | 40 | 0.910 |
Why?
|
| Anthocyanins | 6 | 2019 | 31 | 0.900 |
Why?
|
| beta Catenin | 9 | 2018 | 220 | 0.900 |
Why?
|
| Azoxymethane | 7 | 2022 | 19 | 0.890 |
Why?
|
| Naproxen | 1 | 2024 | 17 | 0.890 |
Why?
|
| Oncogene Fusion | 1 | 2024 | 14 | 0.890 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 9 | 2017 | 151 | 0.880 |
Why?
|
| DNA-Binding Proteins | 12 | 2015 | 1443 | 0.880 |
Why?
|
| Exosomes | 3 | 2020 | 96 | 0.860 |
Why?
|
| G1 Phase | 8 | 2009 | 70 | 0.850 |
Why?
|
| Patched-1 Receptor | 2 | 2022 | 16 | 0.840 |
Why?
|
| Cyclin-Dependent Kinases | 11 | 2008 | 130 | 0.830 |
Why?
|
| Endoplasmic Reticulum Stress | 6 | 2017 | 101 | 0.830 |
Why?
|
| Carcinoma, Squamous Cell | 8 | 2017 | 623 | 0.830 |
Why?
|
| Cell Transformation, Neoplastic | 6 | 2022 | 328 | 0.820 |
Why?
|
| Cyclin D1 | 12 | 2019 | 63 | 0.820 |
Why?
|
| ErbB Receptors | 6 | 2017 | 606 | 0.810 |
Why?
|
| Cyclins | 10 | 2009 | 89 | 0.810 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 8 | 2017 | 184 | 0.780 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 10 | 2017 | 1049 | 0.770 |
Why?
|
| Bone Morphogenetic Protein 2 | 2 | 2019 | 63 | 0.760 |
Why?
|
| Carcinogens | 8 | 2013 | 110 | 0.750 |
Why?
|
| Deoxycytidine | 2 | 2020 | 163 | 0.750 |
Why?
|
| Neoplasms, Hormone-Dependent | 4 | 2008 | 38 | 0.750 |
Why?
|
| Indoles | 4 | 2019 | 383 | 0.750 |
Why?
|
| Autophagy | 7 | 2018 | 267 | 0.740 |
Why?
|
| Tumor Suppressor Proteins | 9 | 2019 | 317 | 0.730 |
Why?
|
| Mast Cells | 3 | 2019 | 142 | 0.720 |
Why?
|
| Peroxidase | 8 | 2015 | 173 | 0.720 |
Why?
|
| Neoplasm Metastasis | 8 | 2020 | 610 | 0.710 |
Why?
|
| Mice, Transgenic | 13 | 2019 | 2111 | 0.710 |
Why?
|
| Flavonoids | 6 | 2017 | 78 | 0.710 |
Why?
|
| Matrix Metalloproteinases | 2 | 2020 | 90 | 0.700 |
Why?
|
| Aspirin | 1 | 2024 | 379 | 0.700 |
Why?
|
| Cation Transport Proteins | 1 | 2022 | 132 | 0.700 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2017 | 1565 | 0.700 |
Why?
|
| Tumor Microenvironment | 2 | 2016 | 634 | 0.700 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 5 | 2017 | 442 | 0.690 |
Why?
|
| Proto-Oncogene Proteins | 8 | 2005 | 637 | 0.690 |
Why?
|
| Stem Cells | 1 | 2025 | 577 | 0.690 |
Why?
|
| Cell Death | 11 | 2023 | 354 | 0.690 |
Why?
|
| Flavonolignans | 5 | 2012 | 10 | 0.690 |
Why?
|
| Reactive Oxygen Species | 13 | 2023 | 595 | 0.680 |
Why?
|
| Cell Line | 11 | 2020 | 2777 | 0.680 |
Why?
|
| Drug Resistance | 1 | 2020 | 166 | 0.670 |
Why?
|
| Mice, Inbred C57BL | 19 | 2024 | 5408 | 0.670 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 4 | 2016 | 270 | 0.660 |
Why?
|
| Proton Magnetic Resonance Spectroscopy | 2 | 2019 | 21 | 0.650 |
Why?
|
| Corneal Stroma | 2 | 2017 | 17 | 0.650 |
Why?
|
| Doxorubicin | 5 | 2017 | 325 | 0.650 |
Why?
|
| Stilbenes | 5 | 2015 | 36 | 0.650 |
Why?
|
| Biological Products | 2 | 2015 | 199 | 0.620 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 6 | 2010 | 39 | 0.620 |
Why?
|
| Protein Kinases | 3 | 2013 | 318 | 0.610 |
Why?
|
| Sesquiterpenes | 3 | 2016 | 53 | 0.610 |
Why?
|
| Biomarkers, Tumor | 7 | 2020 | 1181 | 0.610 |
Why?
|
| Mitochondria | 11 | 2017 | 875 | 0.610 |
Why?
|
| Inflammation Mediators | 5 | 2024 | 505 | 0.600 |
Why?
|
| Oximes | 2 | 2024 | 22 | 0.600 |
Why?
|
| MicroRNAs | 3 | 2020 | 675 | 0.600 |
Why?
|
| Nuclear Proteins | 4 | 2015 | 663 | 0.570 |
Why?
|
| Dermis | 2 | 2015 | 31 | 0.560 |
Why?
|
| STAT1 Transcription Factor | 4 | 2013 | 70 | 0.560 |
Why?
|
| Head and Neck Neoplasms | 5 | 2015 | 539 | 0.560 |
Why?
|
| Poly(ADP-ribose) Polymerases | 12 | 2019 | 94 | 0.560 |
Why?
|
| Proliferating Cell Nuclear Antigen | 10 | 2010 | 52 | 0.560 |
Why?
|
| Interleukin-8 | 4 | 2021 | 262 | 0.550 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2020 | 269 | 0.550 |
Why?
|
| Integrins | 2 | 2015 | 94 | 0.550 |
Why?
|
| Carcinoma, Transitional Cell | 3 | 2008 | 60 | 0.550 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 2 | 2018 | 8 | 0.540 |
Why?
|
| Drug Delivery Systems | 2 | 2014 | 335 | 0.540 |
Why?
|
| Doxycycline | 2 | 2017 | 59 | 0.530 |
Why?
|
| Intestine, Small | 3 | 2014 | 150 | 0.520 |
Why?
|
| Proteomics | 5 | 2024 | 1061 | 0.520 |
Why?
|
| Necrosis | 2 | 2015 | 232 | 0.520 |
Why?
|
| Time Factors | 15 | 2017 | 6549 | 0.520 |
Why?
|
| Alkylating Agents | 2 | 2013 | 24 | 0.520 |
Why?
|
| NFATC Transcription Factors | 2 | 2016 | 81 | 0.520 |
Why?
|
| Lipogenesis | 1 | 2016 | 59 | 0.510 |
Why?
|
| NADH, NADPH Oxidoreductases | 1 | 2016 | 17 | 0.510 |
Why?
|
| In Situ Nick-End Labeling | 11 | 2015 | 124 | 0.510 |
Why?
|
| Drug Screening Assays, Antitumor | 10 | 2021 | 195 | 0.500 |
Why?
|
| Cytochromes c | 6 | 2016 | 60 | 0.500 |
Why?
|
| Disease Progression | 12 | 2017 | 2622 | 0.500 |
Why?
|
| Chemokine CCL2 | 1 | 2016 | 118 | 0.500 |
Why?
|
| Histones | 9 | 2019 | 588 | 0.490 |
Why?
|
| Hydroxamic Acids | 2 | 2013 | 88 | 0.490 |
Why?
|
| Gallic Acid | 4 | 2009 | 13 | 0.490 |
Why?
|
| Flavones | 3 | 2017 | 10 | 0.490 |
Why?
|
| Epidermal Growth Factor | 5 | 2013 | 171 | 0.490 |
Why?
|
| Microscopy, Confocal | 5 | 2015 | 310 | 0.480 |
Why?
|
| Receptors, Androgen | 3 | 2013 | 147 | 0.480 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2006 | 71 | 0.470 |
Why?
|
| Hematopoietic System | 1 | 2014 | 8 | 0.470 |
Why?
|
| Oxidation-Reduction | 9 | 2020 | 1026 | 0.470 |
Why?
|
| Glutathione | 3 | 2011 | 348 | 0.470 |
Why?
|
| Interleukin-4 | 3 | 2014 | 212 | 0.470 |
Why?
|
| Spheroids, Cellular | 2 | 2019 | 77 | 0.460 |
Why?
|
| CDC2 Protein Kinase | 5 | 2006 | 31 | 0.460 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2014 | 202 | 0.460 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2014 | 57 | 0.460 |
Why?
|
| Retinoblastoma Protein | 3 | 2004 | 54 | 0.460 |
Why?
|
| Cytokines | 6 | 2024 | 2011 | 0.460 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2013 | 209 | 0.450 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 3390 | 0.450 |
Why?
|
| Fibronectins | 1 | 2014 | 122 | 0.440 |
Why?
|
| Hyperkeratosis, Epidermolytic | 1 | 2014 | 21 | 0.440 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2014 | 40 | 0.440 |
Why?
|
| Up-Regulation | 6 | 2013 | 837 | 0.440 |
Why?
|
| AMP-Activated Protein Kinases | 5 | 2017 | 189 | 0.430 |
Why?
|
| Epigenesis, Genetic | 3 | 2013 | 613 | 0.430 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2014 | 35 | 0.430 |
Why?
|
| HT29 Cells | 7 | 2018 | 36 | 0.430 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 6 | 2017 | 66 | 0.430 |
Why?
|
| Plant Lectins | 3 | 2018 | 8 | 0.420 |
Why?
|
| Carboplatin | 2 | 2004 | 140 | 0.420 |
Why?
|
| Momordica | 1 | 2013 | 2 | 0.420 |
Why?
|
| Cell Growth Processes | 7 | 2016 | 52 | 0.420 |
Why?
|
| Radiation-Protective Agents | 3 | 2013 | 26 | 0.420 |
Why?
|
| Protein Biosynthesis | 2 | 2013 | 401 | 0.420 |
Why?
|
| Cells, Cultured | 13 | 2019 | 4072 | 0.410 |
Why?
|
| Epithelial Cells | 5 | 2019 | 1064 | 0.410 |
Why?
|
| Structure-Activity Relationship | 8 | 2021 | 548 | 0.410 |
Why?
|
| E2F Transcription Factors | 4 | 2006 | 59 | 0.410 |
Why?
|
| Adenomatous Polyposis Coli Protein | 2 | 2010 | 20 | 0.410 |
Why?
|
| Chromatography, Liquid | 3 | 2024 | 415 | 0.410 |
Why?
|
| RANK Ligand | 1 | 2012 | 26 | 0.410 |
Why?
|
| Androgens | 3 | 2018 | 177 | 0.400 |
Why?
|
| Molecular Structure | 10 | 2021 | 480 | 0.400 |
Why?
|
| Osteoclasts | 1 | 2012 | 42 | 0.400 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 7 | 2013 | 832 | 0.400 |
Why?
|
| Spleen | 1 | 2014 | 506 | 0.400 |
Why?
|
| Comfrey | 1 | 2012 | 2 | 0.400 |
Why?
|
| Glyceric Acids | 1 | 2012 | 6 | 0.400 |
Why?
|
| Oryza | 3 | 2022 | 31 | 0.400 |
Why?
|
| Interleukin-12 | 1 | 2013 | 118 | 0.390 |
Why?
|
| Corneal Diseases | 1 | 2012 | 34 | 0.390 |
Why?
|
| Acetylcysteine | 4 | 2023 | 146 | 0.390 |
Why?
|
| cdc25 Phosphatases | 3 | 2008 | 15 | 0.390 |
Why?
|
| Immunoblotting | 10 | 2017 | 304 | 0.390 |
Why?
|
| Models, Biological | 8 | 2016 | 1718 | 0.380 |
Why?
|
| S-Phase Kinase-Associated Proteins | 2 | 2012 | 20 | 0.380 |
Why?
|
| Pyrimidine Dimers | 3 | 2011 | 6 | 0.380 |
Why?
|
| Tandem Mass Spectrometry | 3 | 2024 | 515 | 0.380 |
Why?
|
| Photosensitizing Agents | 1 | 2012 | 31 | 0.380 |
Why?
|
| Cell Hypoxia | 4 | 2016 | 234 | 0.380 |
Why?
|
| Cisplatin | 2 | 2004 | 298 | 0.380 |
Why?
|
| Administration, Cutaneous | 3 | 2017 | 123 | 0.360 |
Why?
|
| Breast Neoplasms | 5 | 2023 | 2142 | 0.360 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2011 | 1195 | 0.360 |
Why?
|
| Dietary Supplements | 5 | 2014 | 531 | 0.350 |
Why?
|
| Inhibitor of Apoptosis Proteins | 6 | 2011 | 45 | 0.350 |
Why?
|
| Interleukin-6 | 1 | 2014 | 720 | 0.340 |
Why?
|
| Transplantation, Heterologous | 7 | 2009 | 192 | 0.340 |
Why?
|
| Biflavonoids | 3 | 2019 | 9 | 0.340 |
Why?
|
| Proanthocyanidins | 3 | 2019 | 10 | 0.340 |
Why?
|
| Corneal Keratocytes | 2 | 2021 | 10 | 0.340 |
Why?
|
| Catechin | 3 | 2019 | 24 | 0.330 |
Why?
|
| Edema | 3 | 2017 | 124 | 0.330 |
Why?
|
| Anti-Bacterial Agents | 2 | 2017 | 1711 | 0.330 |
Why?
|
| Endothelial Cells | 5 | 2015 | 740 | 0.330 |
Why?
|
| Dermatitis, Irritant | 1 | 2009 | 10 | 0.330 |
Why?
|
| Cosmetics | 1 | 2009 | 8 | 0.330 |
Why?
|
| RNA, Small Interfering | 5 | 2015 | 584 | 0.330 |
Why?
|
| Peptides | 1 | 2015 | 924 | 0.320 |
Why?
|
| Kava | 1 | 2008 | 2 | 0.310 |
Why?
|
| Cell Differentiation | 8 | 2018 | 1899 | 0.310 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2008 | 26 | 0.310 |
Why?
|
| Drug Synergism | 5 | 2013 | 369 | 0.310 |
Why?
|
| Female | 29 | 2023 | 68607 | 0.310 |
Why?
|
| Interferon-gamma | 2 | 2011 | 769 | 0.310 |
Why?
|
| Immunoenzyme Techniques | 5 | 2013 | 213 | 0.310 |
Why?
|
| Skinfold Thickness | 3 | 2013 | 46 | 0.300 |
Why?
|
| Macrophages | 3 | 2019 | 1478 | 0.300 |
Why?
|
| Caspase 9 | 2 | 2013 | 55 | 0.300 |
Why?
|
| Erythema | 3 | 2024 | 28 | 0.300 |
Why?
|
| Metformin | 1 | 2012 | 315 | 0.290 |
Why?
|
| Blood Vessels | 2 | 2021 | 187 | 0.290 |
Why?
|
| Butylhydroxybutylnitrosamine | 1 | 2007 | 6 | 0.290 |
Why?
|
| Energy Metabolism | 2 | 2014 | 869 | 0.290 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2008 | 55 | 0.290 |
Why?
|
| Autocrine Communication | 1 | 2008 | 43 | 0.290 |
Why?
|
| Transfection | 5 | 2014 | 908 | 0.290 |
Why?
|
| Cytotoxins | 1 | 2007 | 16 | 0.290 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2009 | 359 | 0.280 |
Why?
|
| Neoplasm Transplantation | 6 | 2014 | 257 | 0.280 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 958 | 0.280 |
Why?
|
| Food | 2 | 2015 | 156 | 0.280 |
Why?
|
| Clinical Trials as Topic | 6 | 2020 | 1004 | 0.280 |
Why?
|
| Flow Cytometry | 7 | 2010 | 1156 | 0.280 |
Why?
|
| Tannins | 1 | 2007 | 5 | 0.280 |
Why?
|
| Mice, Knockout | 4 | 2016 | 2856 | 0.280 |
Why?
|
| Cell Nucleus | 4 | 2016 | 582 | 0.280 |
Why?
|
| Cyclin-Dependent Kinase 4 | 5 | 2012 | 44 | 0.270 |
Why?
|
| Kidney | 1 | 2014 | 1375 | 0.270 |
Why?
|
| Precancerous Conditions | 1 | 2008 | 162 | 0.270 |
Why?
|
| Models, Animal | 3 | 2020 | 373 | 0.270 |
Why?
|
| Administration, Oral | 6 | 2011 | 783 | 0.270 |
Why?
|
| Organ Culture Techniques | 2 | 2017 | 154 | 0.260 |
Why?
|
| Caspase 2 | 1 | 2006 | 13 | 0.260 |
Why?
|
| Gene Expression Regulation | 2 | 2013 | 2543 | 0.260 |
Why?
|
| Cyclin-Dependent Kinase 2 | 4 | 2012 | 39 | 0.260 |
Why?
|
| Growth Inhibitors | 4 | 2013 | 44 | 0.260 |
Why?
|
| Cytochrome c Group | 2 | 2003 | 42 | 0.260 |
Why?
|
| RNA, Messenger | 5 | 2010 | 2702 | 0.260 |
Why?
|
| Intracellular Membranes | 2 | 2004 | 83 | 0.260 |
Why?
|
| Body Weight | 4 | 2014 | 938 | 0.260 |
Why?
|
| DNA | 3 | 2010 | 1399 | 0.250 |
Why?
|
| Tyrosine | 2 | 2013 | 223 | 0.250 |
Why?
|
| CDC2-CDC28 Kinases | 2 | 2004 | 20 | 0.250 |
Why?
|
| Biomedical Research | 1 | 2011 | 637 | 0.240 |
Why?
|
| Wnt Proteins | 3 | 2018 | 127 | 0.240 |
Why?
|
| S Phase | 1 | 2005 | 75 | 0.240 |
Why?
|
| Plants | 1 | 2007 | 215 | 0.240 |
Why?
|
| Cytoprotection | 3 | 2015 | 56 | 0.240 |
Why?
|
| Benzopyrans | 1 | 2005 | 31 | 0.240 |
Why?
|
| Rad51 Recombinase | 2 | 2015 | 13 | 0.230 |
Why?
|
| Glycosides | 1 | 2005 | 37 | 0.230 |
Why?
|
| Liver Neoplasms | 2 | 2008 | 640 | 0.230 |
Why?
|
| Butyrates | 1 | 2005 | 56 | 0.230 |
Why?
|
| Deoxyguanosine | 2 | 2015 | 25 | 0.220 |
Why?
|
| Cysteine | 2 | 2020 | 194 | 0.220 |
Why?
|
| Insulin-Like Growth Factor I | 4 | 2018 | 307 | 0.220 |
Why?
|
| HCT116 Cells | 3 | 2014 | 78 | 0.220 |
Why?
|
| Unfolded Protein Response | 1 | 2023 | 53 | 0.210 |
Why?
|
| Lipid Metabolism | 4 | 2020 | 497 | 0.210 |
Why?
|
| Intestinal Mucosa | 1 | 2008 | 590 | 0.210 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2005 | 272 | 0.210 |
Why?
|
| Pentacyclic Triterpenes | 2 | 2014 | 15 | 0.210 |
Why?
|
| Neoplasms, Experimental | 1 | 2024 | 171 | 0.210 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 5 | 2015 | 101 | 0.210 |
Why?
|
| Actin Cytoskeleton | 1 | 2024 | 104 | 0.210 |
Why?
|
| Nucleotides | 1 | 2023 | 122 | 0.200 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2015 | 84 | 0.200 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2024 | 161 | 0.200 |
Why?
|
| Bifidobacterium longum | 1 | 2022 | 6 | 0.200 |
Why?
|
| In Vitro Techniques | 2 | 2016 | 1083 | 0.200 |
Why?
|
| Carcinoma, Small Cell | 1 | 2003 | 169 | 0.200 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 3 | 2009 | 55 | 0.190 |
Why?
|
| Nitric Oxide Synthase Type III | 4 | 2013 | 203 | 0.190 |
Why?
|
| Cell Cycle Checkpoints | 4 | 2016 | 95 | 0.190 |
Why?
|
| Organ Size | 2 | 2014 | 445 | 0.190 |
Why?
|
| Mitochondrial Proteins | 1 | 2004 | 246 | 0.190 |
Why?
|
| Mice, Inbred BALB C | 3 | 2013 | 1243 | 0.190 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 2 | 2012 | 29 | 0.190 |
Why?
|
| Ligands | 1 | 2024 | 621 | 0.190 |
Why?
|
| Carrier Proteins | 2 | 2022 | 740 | 0.190 |
Why?
|
| Actins | 1 | 2024 | 408 | 0.190 |
Why?
|
| Endothelium, Vascular | 2 | 2005 | 898 | 0.190 |
Why?
|
| Solid-Phase Synthesis Techniques | 1 | 2021 | 12 | 0.180 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 2 | 2017 | 43 | 0.180 |
Why?
|
| Protein Transport | 3 | 2011 | 425 | 0.180 |
Why?
|
| Bromodeoxyuridine | 3 | 2007 | 77 | 0.180 |
Why?
|
| Curcumin | 1 | 2021 | 29 | 0.180 |
Why?
|
| Biological Assay | 2 | 2016 | 118 | 0.180 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2015 | 287 | 0.180 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 3 | 2015 | 131 | 0.180 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2019 | 182 | 0.170 |
Why?
|
| Chromones | 2 | 2014 | 45 | 0.170 |
Why?
|
| Radiation Tolerance | 2 | 2015 | 100 | 0.170 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2022 | 201 | 0.170 |
Why?
|
| Mitosis | 3 | 2007 | 179 | 0.170 |
Why?
|
| Tumor Hypoxia | 1 | 2020 | 6 | 0.170 |
Why?
|
| Aldehydes | 2 | 2012 | 143 | 0.170 |
Why?
|
| Caspase 8 | 2 | 2010 | 48 | 0.170 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2020 | 91 | 0.170 |
Why?
|
| Intestinal Polyps | 2 | 2010 | 17 | 0.170 |
Why?
|
| Immunity | 1 | 2020 | 139 | 0.170 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2019 | 23 | 0.170 |
Why?
|
| Mitogens | 2 | 2013 | 58 | 0.160 |
Why?
|
| Species Specificity | 2 | 2013 | 574 | 0.160 |
Why?
|
| Janus Kinase 1 | 2 | 2011 | 24 | 0.160 |
Why?
|
| Ovarian Neoplasms | 1 | 2005 | 487 | 0.160 |
Why?
|
| Lipids | 1 | 2023 | 624 | 0.160 |
Why?
|
| Proprotein Convertase 9 | 1 | 2020 | 68 | 0.160 |
Why?
|
| Antiviral Agents | 2 | 2018 | 712 | 0.160 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2020 | 34 | 0.160 |
Why?
|
| Gene Expression | 3 | 2015 | 1469 | 0.160 |
Why?
|
| Protein Carbonylation | 1 | 2019 | 56 | 0.160 |
Why?
|
| Hypoxia | 2 | 2019 | 1079 | 0.160 |
Why?
|
| Phosphoproteins | 1 | 2002 | 331 | 0.160 |
Why?
|
| Morpholines | 2 | 2014 | 122 | 0.160 |
Why?
|
| Mice, Inbred Strains | 4 | 2017 | 406 | 0.160 |
Why?
|
| Cyclin E | 2 | 2012 | 23 | 0.160 |
Why?
|
| Respiratory System | 1 | 2020 | 153 | 0.160 |
Why?
|
| Pesticides | 1 | 2019 | 58 | 0.160 |
Why?
|
| DNA, Neoplasm | 2 | 2010 | 159 | 0.160 |
Why?
|
| Triterpenes | 2 | 2010 | 20 | 0.160 |
Why?
|
| Lanosterol | 2 | 2009 | 2 | 0.160 |
Why?
|
| Membrane Potentials | 3 | 2005 | 291 | 0.160 |
Why?
|
| Lipid Peroxidation | 2 | 2019 | 151 | 0.160 |
Why?
|
| Oncogene Protein v-akt | 2 | 2009 | 24 | 0.160 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2010 | 171 | 0.160 |
Why?
|
| Cytosol | 2 | 2013 | 218 | 0.150 |
Why?
|
| Urethane | 2 | 2010 | 41 | 0.150 |
Why?
|
| Body Fluids | 1 | 2019 | 62 | 0.150 |
Why?
|
| G2 Phase | 3 | 2012 | 36 | 0.150 |
Why?
|
| Secondary Prevention | 1 | 2020 | 218 | 0.150 |
Why?
|
| Zinc | 1 | 2022 | 293 | 0.150 |
Why?
|
| Kinetics | 3 | 2014 | 1641 | 0.150 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2012 | 132 | 0.150 |
Why?
|
| Dermatitis | 2 | 2010 | 19 | 0.150 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2018 | 10 | 0.150 |
Why?
|
| CD24 Antigen | 1 | 2018 | 20 | 0.150 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 3 | 2016 | 257 | 0.150 |
Why?
|
| Fruit and Vegetable Juices | 1 | 2018 | 15 | 0.150 |
Why?
|
| Tumor Burden | 3 | 2020 | 285 | 0.150 |
Why?
|
| Culture Media, Conditioned | 2 | 2016 | 110 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 2 | 2012 | 16 | 0.150 |
Why?
|
| Glycoconjugates | 1 | 2018 | 8 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor Proteins | 2 | 2008 | 7 | 0.150 |
Why?
|
| Corneal Pachymetry | 1 | 2017 | 15 | 0.150 |
Why?
|
| Checkpoint Kinase 2 | 3 | 2006 | 25 | 0.150 |
Why?
|
| Arsenic Poisoning | 1 | 2017 | 7 | 0.150 |
Why?
|
| Hyaluronan Receptors | 1 | 2018 | 96 | 0.140 |
Why?
|
| Keratitis | 1 | 2017 | 14 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2012 | 69 | 0.140 |
Why?
|
| Dual Specificity Phosphatase 6 | 1 | 2017 | 6 | 0.140 |
Why?
|
| Tumor Protein p73 | 1 | 2017 | 14 | 0.140 |
Why?
|
| Transcriptional Activation | 2 | 2010 | 365 | 0.140 |
Why?
|
| Dimerization | 3 | 2011 | 191 | 0.140 |
Why?
|
| Cholesterol, LDL | 1 | 2020 | 358 | 0.140 |
Why?
|
| Laminin | 3 | 2013 | 69 | 0.140 |
Why?
|
| Treatment Outcome | 5 | 2016 | 10189 | 0.140 |
Why?
|
| Glucose | 2 | 2015 | 1000 | 0.140 |
Why?
|
| Triglycerides | 2 | 2020 | 527 | 0.140 |
Why?
|
| Microcirculation | 2 | 2008 | 145 | 0.140 |
Why?
|
| Autophagy-Related Protein-1 Homolog | 1 | 2017 | 7 | 0.140 |
Why?
|
| Receptors, Notch | 1 | 2018 | 84 | 0.140 |
Why?
|
| Organophosphates | 1 | 2018 | 120 | 0.140 |
Why?
|
| Heterografts | 2 | 2015 | 131 | 0.140 |
Why?
|
| Proteoglycans | 3 | 2013 | 110 | 0.140 |
Why?
|
| Diet | 4 | 2022 | 1212 | 0.140 |
Why?
|
| Proteins | 2 | 2003 | 939 | 0.140 |
Why?
|
| Consensus | 1 | 2020 | 612 | 0.130 |
Why?
|
| Autophagy-Related Proteins | 1 | 2017 | 42 | 0.130 |
Why?
|
| Mouth Neoplasms | 1 | 2017 | 86 | 0.130 |
Why?
|
| Adipose Tissue | 1 | 2020 | 590 | 0.130 |
Why?
|
| Proteome | 2 | 2019 | 443 | 0.130 |
Why?
|
| Pleckstrin Homology Domains | 1 | 2016 | 1 | 0.130 |
Why?
|
| Tumor Stem Cell Assay | 2 | 2014 | 32 | 0.130 |
Why?
|
| Ribosome Inactivating Proteins, Type 2 | 1 | 2016 | 2 | 0.130 |
Why?
|
| HIV | 1 | 2018 | 226 | 0.130 |
Why?
|
| Administration, Topical | 2 | 2008 | 145 | 0.130 |
Why?
|
| Talaromyces | 1 | 2016 | 4 | 0.130 |
Why?
|
| Protein Binding | 3 | 2017 | 2119 | 0.130 |
Why?
|
| NADPH Oxidase 1 | 1 | 2016 | 2 | 0.130 |
Why?
|
| Annonaceae | 1 | 2016 | 4 | 0.130 |
Why?
|
| Drug Combinations | 3 | 2013 | 327 | 0.130 |
Why?
|
| Corneal Opacity | 1 | 2016 | 7 | 0.130 |
Why?
|
| Acute Disease | 1 | 2019 | 977 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 389 | 0.130 |
Why?
|
| Terpenes | 1 | 2016 | 21 | 0.130 |
Why?
|
| NADPH Oxidase 2 | 1 | 2016 | 38 | 0.130 |
Why?
|
| Xeroderma Pigmentosum Group A Protein | 1 | 2015 | 5 | 0.130 |
Why?
|
| Societies, Medical | 1 | 2020 | 747 | 0.130 |
Why?
|
| Pyrones | 1 | 2015 | 9 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 64 | 0.130 |
Why?
|
| NADPH Oxidases | 1 | 2016 | 108 | 0.120 |
Why?
|
| Naphthols | 1 | 2015 | 8 | 0.120 |
Why?
|
| Rupture | 1 | 2016 | 89 | 0.120 |
Why?
|
| Solanum tuberosum | 1 | 2015 | 7 | 0.120 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2015 | 40 | 0.120 |
Why?
|
| Metabolome | 1 | 2019 | 338 | 0.120 |
Why?
|
| Skin Absorption | 1 | 2015 | 12 | 0.120 |
Why?
|
| Stomach Neoplasms | 1 | 2016 | 98 | 0.120 |
Why?
|
| Eye | 1 | 2016 | 104 | 0.120 |
Why?
|
| Naphthalenes | 1 | 2015 | 57 | 0.120 |
Why?
|
| Transforming Growth Factor beta | 1 | 2018 | 457 | 0.120 |
Why?
|
| Collagen | 3 | 2013 | 434 | 0.120 |
Why?
|
| Electron Transport Complex III | 1 | 2014 | 15 | 0.120 |
Why?
|
| Microsomes, Liver | 2 | 2012 | 86 | 0.120 |
Why?
|
| Metribolone | 1 | 2014 | 5 | 0.120 |
Why?
|
| Sterol Regulatory Element Binding Protein 2 | 1 | 2014 | 8 | 0.120 |
Why?
|
| Neoplasm Staging | 3 | 2019 | 1292 | 0.120 |
Why?
|
| Quinazolines | 1 | 2016 | 244 | 0.120 |
Why?
|
| Extracellular Matrix | 2 | 2019 | 503 | 0.120 |
Why?
|
| Colon | 2 | 2022 | 252 | 0.120 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2022 | 640 | 0.120 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2015 | 128 | 0.120 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2014 | 15 | 0.110 |
Why?
|
| Peptide Hydrolases | 1 | 2015 | 107 | 0.110 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2014 | 44 | 0.110 |
Why?
|
| Snail Family Transcription Factors | 1 | 2014 | 18 | 0.110 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2014 | 45 | 0.110 |
Why?
|
| Thiazoles | 1 | 2014 | 117 | 0.110 |
Why?
|
| Glucuronides | 2 | 2011 | 18 | 0.110 |
Why?
|
| DNA Helicases | 1 | 2015 | 149 | 0.110 |
Why?
|
| Allografts | 1 | 2014 | 136 | 0.110 |
Why?
|
| Boron Compounds | 1 | 2014 | 22 | 0.110 |
Why?
|
| 4-Nitroquinoline-1-oxide | 1 | 2013 | 8 | 0.110 |
Why?
|
| Leukocyte Count | 1 | 2014 | 325 | 0.110 |
Why?
|
| Caspase Inhibitors | 2 | 2004 | 83 | 0.110 |
Why?
|
| Glioma | 2 | 2011 | 354 | 0.110 |
Why?
|
| Adherens Junctions | 1 | 2013 | 25 | 0.110 |
Why?
|
| Protein Processing, Post-Translational | 3 | 2014 | 454 | 0.110 |
Why?
|
| Tongue Neoplasms | 1 | 2013 | 23 | 0.110 |
Why?
|
| Metalloporphyrins | 1 | 2014 | 101 | 0.110 |
Why?
|
| Membrane Glycoproteins | 1 | 2016 | 473 | 0.110 |
Why?
|
| Extracellular Vesicles | 1 | 2015 | 130 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2011 | 232 | 0.110 |
Why?
|
| Antigens, CD | 1 | 2016 | 488 | 0.110 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2013 | 24 | 0.100 |
Why?
|
| Somatomedins | 1 | 2013 | 28 | 0.100 |
Why?
|
| Vacuoles | 1 | 2013 | 36 | 0.100 |
Why?
|
| Adipocytes | 1 | 2014 | 205 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 1364 | 0.100 |
Why?
|
| Cell Shape | 1 | 2013 | 55 | 0.100 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 315 | 0.100 |
Why?
|
| Annexin A5 | 2 | 2002 | 23 | 0.100 |
Why?
|
| Dietary Fiber | 1 | 2013 | 50 | 0.100 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2012 | 376 | 0.100 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2012 | 538 | 0.100 |
Why?
|
| Rats | 5 | 2013 | 5462 | 0.100 |
Why?
|
| Cyclin B1 | 1 | 2012 | 6 | 0.100 |
Why?
|
| E2F4 Transcription Factor | 2 | 2003 | 8 | 0.100 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2012 | 39 | 0.100 |
Why?
|
| Models, Chemical | 2 | 2006 | 265 | 0.100 |
Why?
|
| A549 Cells | 3 | 2017 | 58 | 0.100 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2012 | 48 | 0.100 |
Why?
|
| Macrolides | 1 | 2013 | 63 | 0.100 |
Why?
|
| Plant Preparations | 1 | 2012 | 31 | 0.100 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 3 | 2019 | 161 | 0.100 |
Why?
|
| beta-Transducin Repeat-Containing Proteins | 1 | 2012 | 2 | 0.100 |
Why?
|
| E2F3 Transcription Factor | 2 | 2002 | 10 | 0.100 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2012 | 83 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2012 | 13 | 0.100 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 285 | 0.100 |
Why?
|
| S Phase Cell Cycle Checkpoints | 1 | 2011 | 4 | 0.100 |
Why?
|
| Gene Silencing | 1 | 2013 | 187 | 0.100 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 3 | 2007 | 178 | 0.100 |
Why?
|
| Transcription Factor CHOP | 1 | 2012 | 30 | 0.100 |
Why?
|
| Genes, erbB-1 | 1 | 2011 | 17 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2012 | 40 | 0.100 |
Why?
|
| Azacitidine | 1 | 2013 | 139 | 0.090 |
Why?
|
| Oxygen Consumption | 1 | 2015 | 672 | 0.090 |
Why?
|
| Chromans | 1 | 2011 | 24 | 0.090 |
Why?
|
| Rats, Inbred F344 | 2 | 2010 | 257 | 0.090 |
Why?
|
| Acetylation | 1 | 2012 | 246 | 0.090 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2012 | 61 | 0.090 |
Why?
|
| Stress, Physiological | 1 | 2014 | 413 | 0.090 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2011 | 55 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2014 | 1271 | 0.090 |
Why?
|
| Flavonols | 3 | 2017 | 12 | 0.090 |
Why?
|
| Random Allocation | 2 | 2010 | 346 | 0.090 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2013 | 168 | 0.090 |
Why?
|
| Smad4 Protein | 1 | 2011 | 38 | 0.090 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2011 | 71 | 0.090 |
Why?
|
| Glioblastoma | 1 | 2014 | 326 | 0.090 |
Why?
|
| Brain Neoplasms | 2 | 2014 | 1170 | 0.090 |
Why?
|
| Hepacivirus | 1 | 2012 | 235 | 0.090 |
Why?
|
| Buthionine Sulfoximine | 1 | 2010 | 8 | 0.090 |
Why?
|
| Pyridines | 1 | 2014 | 478 | 0.090 |
Why?
|
| Nestin | 1 | 2010 | 19 | 0.090 |
Why?
|
| Adenine | 1 | 2013 | 256 | 0.090 |
Why?
|
| Intermediate Filament Proteins | 1 | 2010 | 57 | 0.090 |
Why?
|
| Angiogenic Proteins | 1 | 2010 | 16 | 0.090 |
Why?
|
| Oxygen | 1 | 2015 | 911 | 0.090 |
Why?
|
| X-Ray Microtomography | 1 | 2010 | 84 | 0.090 |
Why?
|
| src-Family Kinases | 1 | 2011 | 96 | 0.090 |
Why?
|
| Genes, APC | 1 | 2010 | 13 | 0.090 |
Why?
|
| Neovascularization, Physiologic | 1 | 2011 | 176 | 0.090 |
Why?
|
| Alleles | 1 | 2013 | 845 | 0.090 |
Why?
|
| Phenotype | 1 | 2019 | 3074 | 0.090 |
Why?
|
| Thyroid Neoplasms | 1 | 2014 | 309 | 0.090 |
Why?
|
| Transcription Factor RelA | 1 | 2010 | 81 | 0.080 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2011 | 87 | 0.080 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2013 | 395 | 0.080 |
Why?
|
| Lactoferrin | 1 | 2010 | 28 | 0.080 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2010 | 33 | 0.080 |
Why?
|
| RNA Interference | 1 | 2011 | 447 | 0.080 |
Why?
|
| Deoxyadenosines | 1 | 2009 | 8 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase 8 | 1 | 2010 | 44 | 0.080 |
Why?
|
| Arachidonic Acid | 1 | 2010 | 115 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2010 | 52 | 0.080 |
Why?
|
| NF-KappaB Inhibitor alpha | 2 | 2014 | 49 | 0.080 |
Why?
|
| Cyclic N-Oxides | 1 | 2009 | 30 | 0.080 |
Why?
|
| Phospholipases A | 1 | 2010 | 99 | 0.080 |
Why?
|
| Hepatitis | 1 | 2010 | 47 | 0.080 |
Why?
|
| Skin Care | 1 | 2009 | 21 | 0.080 |
Why?
|
| Skin Aging | 1 | 2009 | 19 | 0.080 |
Why?
|
| Lung | 2 | 2014 | 3916 | 0.080 |
Why?
|
| Intestinal Neoplasms | 1 | 2009 | 28 | 0.080 |
Why?
|
| Esthetics | 1 | 2009 | 49 | 0.080 |
Why?
|
| Endoplasmic Reticulum | 1 | 2012 | 259 | 0.080 |
Why?
|
| Dinoprostone | 1 | 2010 | 186 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 1037 | 0.080 |
Why?
|
| I-kappa B Proteins | 2 | 2014 | 74 | 0.080 |
Why?
|
| Inositol | 1 | 2009 | 26 | 0.080 |
Why?
|
| Citrates | 1 | 2009 | 42 | 0.080 |
Why?
|
| Apiaceae | 1 | 2009 | 1 | 0.080 |
Why?
|
| Furocoumarins | 1 | 2009 | 8 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2010 | 174 | 0.080 |
Why?
|
| Homeodomain Proteins | 1 | 2013 | 494 | 0.080 |
Why?
|
| Gene Deletion | 1 | 2010 | 378 | 0.080 |
Why?
|
| Cell Polarity | 1 | 2010 | 140 | 0.080 |
Why?
|
| Membrane Potential, Mitochondrial | 3 | 2016 | 68 | 0.080 |
Why?
|
| Polyporales | 1 | 2008 | 1 | 0.080 |
Why?
|
| Dermatologic Agents | 1 | 2009 | 65 | 0.080 |
Why?
|
| Plant Roots | 1 | 2009 | 43 | 0.080 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2008 | 12 | 0.080 |
Why?
|
| Fruit | 1 | 2009 | 131 | 0.080 |
Why?
|
| Wound Healing | 1 | 2011 | 303 | 0.080 |
Why?
|
| Principal Component Analysis | 1 | 2009 | 186 | 0.080 |
Why?
|
| Neutrophil Infiltration | 1 | 2008 | 105 | 0.080 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2010 | 375 | 0.080 |
Why?
|
| Isomerism | 1 | 2008 | 50 | 0.080 |
Why?
|
| Antimitotic Agents | 1 | 2008 | 8 | 0.080 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2010 | 132 | 0.080 |
Why?
|
| Vimentin | 1 | 2008 | 51 | 0.080 |
Why?
|
| Oxidative Phosphorylation | 1 | 2009 | 187 | 0.080 |
Why?
|
| Beverages | 1 | 2008 | 68 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2017 | 3234 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2008 | 15 | 0.070 |
Why?
|
| ets-Domain Protein Elk-1 | 2 | 2005 | 13 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 9 | 1 | 2008 | 18 | 0.070 |
Why?
|
| Microvessels | 1 | 2009 | 83 | 0.070 |
Why?
|
| Choline | 1 | 2009 | 123 | 0.070 |
Why?
|
| Mice, Inbred ICR | 1 | 2007 | 110 | 0.070 |
Why?
|
| Mitoxantrone | 1 | 2007 | 14 | 0.070 |
Why?
|
| Luciferases | 1 | 2007 | 148 | 0.070 |
Why?
|
| Immunoprecipitation | 1 | 2007 | 157 | 0.070 |
Why?
|
| Abrus | 2 | 2017 | 2 | 0.070 |
Why?
|
| Monocytes | 1 | 2010 | 551 | 0.070 |
Why?
|
| Janus Kinase 2 | 1 | 2007 | 32 | 0.070 |
Why?
|
| Stereoisomerism | 1 | 2007 | 98 | 0.070 |
Why?
|
| Mutation | 3 | 2020 | 3715 | 0.070 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2007 | 146 | 0.070 |
Why?
|
| Macrophages, Alveolar | 1 | 2010 | 389 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 1 | 2010 | 569 | 0.070 |
Why?
|
| I-kappa B Kinase | 2 | 2003 | 53 | 0.070 |
Why?
|
| Toluene | 1 | 2006 | 11 | 0.070 |
Why?
|
| Brain | 1 | 2019 | 2664 | 0.070 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 2006 | 24 | 0.070 |
Why?
|
| Ornithine Decarboxylase | 1 | 2006 | 10 | 0.070 |
Why?
|
| Benzothiazoles | 1 | 2006 | 32 | 0.060 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2006 | 15 | 0.060 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2006 | 65 | 0.060 |
Why?
|
| Anoikis | 1 | 2006 | 31 | 0.060 |
Why?
|
| Cyclin D3 | 1 | 2005 | 5 | 0.060 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2006 | 85 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2008 | 1285 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 2 | 2007 | 1206 | 0.060 |
Why?
|
| Ataxia Telangiectasia | 1 | 2005 | 17 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 2 | 2011 | 1036 | 0.060 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2005 | 31 | 0.060 |
Why?
|
| Ribonucleotide Reductases | 1 | 2005 | 31 | 0.060 |
Why?
|
| Chrysanthemum | 1 | 2005 | 2 | 0.060 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 2003 | 76 | 0.060 |
Why?
|
| Rhamnose | 1 | 2005 | 3 | 0.060 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2005 | 68 | 0.060 |
Why?
|
| Cycloheximide | 1 | 2004 | 56 | 0.060 |
Why?
|
| Plant Oils | 1 | 2004 | 29 | 0.060 |
Why?
|
| HeLa Cells | 2 | 2017 | 607 | 0.060 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2005 | 79 | 0.060 |
Why?
|
| Light | 1 | 2007 | 353 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2008 | 406 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2008 | 350 | 0.060 |
Why?
|
| Resting Phase, Cell Cycle | 1 | 2003 | 15 | 0.050 |
Why?
|
| Papilloma | 1 | 2003 | 46 | 0.050 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2015 | 55 | 0.050 |
Why?
|
| Animal Feed | 1 | 2004 | 50 | 0.050 |
Why?
|
| Eyelids | 1 | 2024 | 34 | 0.050 |
Why?
|
| Cell Communication | 1 | 2005 | 300 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2004 | 90 | 0.050 |
Why?
|
| Sphingolipids | 1 | 2024 | 71 | 0.050 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2023 | 14 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2003 | 109 | 0.050 |
Why?
|
| Comet Assay | 2 | 2014 | 17 | 0.050 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2016 | 352 | 0.050 |
Why?
|
| Propidium | 1 | 2002 | 8 | 0.050 |
Why?
|
| Trypan Blue | 1 | 2002 | 6 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2006 | 432 | 0.050 |
Why?
|
| Transgenes | 1 | 2003 | 177 | 0.050 |
Why?
|
| Lipoxygenase | 1 | 2002 | 14 | 0.050 |
Why?
|
| Coloring Agents | 1 | 2002 | 76 | 0.050 |
Why?
|
| E2F2 Transcription Factor | 1 | 2002 | 15 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2002 | 94 | 0.050 |
Why?
|
| Electron Transport Complex IV | 1 | 2002 | 57 | 0.050 |
Why?
|
| Mice, Inbred SENCAR | 1 | 2002 | 1 | 0.050 |
Why?
|
| Retinoblastoma-Like Protein p107 | 1 | 2002 | 2 | 0.050 |
Why?
|
| E2F5 Transcription Factor | 1 | 2002 | 3 | 0.050 |
Why?
|
| Retinoblastoma-Like Protein p130 | 1 | 2002 | 4 | 0.050 |
Why?
|
| Dextran Sulfate | 1 | 2022 | 77 | 0.050 |
Why?
|
| E2F1 Transcription Factor | 1 | 2002 | 61 | 0.050 |
Why?
|
| Models, Molecular | 2 | 2017 | 1487 | 0.050 |
Why?
|
| Mammary Glands, Animal | 1 | 2002 | 124 | 0.050 |
Why?
|
| Methylation | 2 | 2012 | 230 | 0.050 |
Why?
|
| Serine | 1 | 2002 | 137 | 0.050 |
Why?
|
| Corticosterone | 1 | 2002 | 218 | 0.050 |
Why?
|
| Cell Separation | 1 | 2002 | 316 | 0.050 |
Why?
|
| Liver | 1 | 2010 | 1838 | 0.050 |
Why?
|
| Organ Specificity | 1 | 2002 | 295 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 2004 | 426 | 0.050 |
Why?
|
| Ranolazine | 1 | 2020 | 25 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2020 | 220 | 0.040 |
Why?
|
| Social Control, Formal | 1 | 2020 | 11 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2003 | 398 | 0.040 |
Why?
|
| Heme Oxygenase-1 | 1 | 2019 | 62 | 0.040 |
Why?
|
| India | 1 | 2020 | 170 | 0.040 |
Why?
|
| Energy Intake | 1 | 2002 | 459 | 0.040 |
Why?
|
| Jagged-1 Protein | 1 | 2019 | 23 | 0.040 |
Why?
|
| Lipoprotein(a) | 1 | 2020 | 67 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2019 | 70 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2005 | 889 | 0.040 |
Why?
|
| Gene Expression Profiling | 2 | 2018 | 1705 | 0.040 |
Why?
|
| Filamins | 1 | 2019 | 28 | 0.040 |
Why?
|
| Receptor, Notch1 | 1 | 2019 | 61 | 0.040 |
Why?
|
| Molecular Imaging | 1 | 2019 | 54 | 0.040 |
Why?
|
| Goals | 1 | 2020 | 160 | 0.040 |
Why?
|
| Interleukin-1 | 1 | 2002 | 958 | 0.040 |
Why?
|
| Fibroblast Growth Factors | 1 | 2019 | 170 | 0.040 |
Why?
|
| Circulating MicroRNA | 1 | 2018 | 25 | 0.040 |
Why?
|
| Proteolysis | 1 | 2018 | 165 | 0.030 |
Why?
|
| A Kinase Anchor Proteins | 1 | 2018 | 71 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2020 | 477 | 0.030 |
Why?
|
| Mouth | 1 | 2017 | 80 | 0.030 |
Why?
|
| Poisoning | 1 | 2017 | 111 | 0.030 |
Why?
|
| Phosphatidylethanolamines | 1 | 2017 | 74 | 0.030 |
Why?
|
| Nuclear Localization Signals | 1 | 2016 | 15 | 0.030 |
Why?
|
| Alkaloids | 1 | 2016 | 25 | 0.030 |
Why?
|
| Gastric Mucosa | 1 | 2016 | 52 | 0.030 |
Why?
|
| eIF-2 Kinase | 1 | 2016 | 30 | 0.030 |
Why?
|
| Animals, Genetically Modified | 1 | 2017 | 229 | 0.030 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2016 | 32 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2016 | 116 | 0.030 |
Why?
|
| Stomach | 1 | 2016 | 109 | 0.030 |
Why?
|
| Penicillium | 1 | 2015 | 6 | 0.030 |
Why?
|
| Diketopiperazines | 1 | 2015 | 12 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2016 | 315 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2016 | 143 | 0.030 |
Why?
|
| Sulindac | 1 | 2015 | 15 | 0.030 |
Why?
|
| Radiation, Ionizing | 1 | 2015 | 76 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 428 | 0.030 |
Why?
|
| Epoxy Compounds | 1 | 2015 | 32 | 0.030 |
Why?
|
| Lentivirus | 1 | 2015 | 53 | 0.030 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2015 | 45 | 0.030 |
Why?
|
| Biopsy | 1 | 2019 | 1087 | 0.030 |
Why?
|
| Lactones | 1 | 2015 | 58 | 0.030 |
Why?
|
| Plant Leaves | 1 | 2016 | 127 | 0.030 |
Why?
|
| Mitochondrial Membranes | 1 | 2014 | 38 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 856 | 0.030 |
Why?
|
| Crystallography, X-Ray | 1 | 2016 | 434 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 758 | 0.030 |
Why?
|
| Dacarbazine | 1 | 2014 | 94 | 0.030 |
Why?
|
| Annexin A2 | 1 | 2013 | 10 | 0.030 |
Why?
|
| Tetraspanins | 1 | 2013 | 19 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2014 | 26 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 285 | 0.030 |
Why?
|
| Peptide Mapping | 1 | 2014 | 63 | 0.030 |
Why?
|
| Chorioallantoic Membrane | 1 | 2013 | 3 | 0.030 |
Why?
|
| Metalloproteases | 1 | 2013 | 44 | 0.030 |
Why?
|
| Tongue | 1 | 2013 | 71 | 0.030 |
Why?
|
| Mice, Inbred A | 1 | 2013 | 48 | 0.030 |
Why?
|
| Chick Embryo | 1 | 2013 | 130 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2016 | 233 | 0.030 |
Why?
|
| Protein Stability | 1 | 2014 | 161 | 0.030 |
Why?
|
| Methionine | 1 | 2014 | 158 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2013 | 226 | 0.030 |
Why?
|
| Cytochrome P-450 CYP2C9 | 1 | 2012 | 20 | 0.030 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2013 | 15 | 0.030 |
Why?
|
| Heat-Shock Proteins | 1 | 2013 | 136 | 0.030 |
Why?
|
| Capillaries | 1 | 2013 | 100 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2012 | 70 | 0.030 |
Why?
|
| Vitamin E | 1 | 2013 | 120 | 0.030 |
Why?
|
| Superoxides | 1 | 2013 | 201 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2013 | 263 | 0.020 |
Why?
|
| Calcium | 1 | 2019 | 1203 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 578 | 0.020 |
Why?
|
| Phenols | 1 | 2013 | 97 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2013 | 440 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1493 | 0.020 |
Why?
|
| Transcriptome | 1 | 2018 | 885 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2013 | 400 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2011 | 141 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2016 | 941 | 0.020 |
Why?
|
| BRCA1 Protein | 1 | 2011 | 65 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 768 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 3067 | 0.020 |
Why?
|
| Concanavalin A | 1 | 2010 | 75 | 0.020 |
Why?
|
| Ethanol | 1 | 2015 | 587 | 0.020 |
Why?
|
| Neurons | 1 | 2019 | 1493 | 0.020 |
Why?
|
| DNA Primers | 1 | 2011 | 510 | 0.020 |
Why?
|
| Prostatectomy | 1 | 2010 | 106 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2010 | 298 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2010 | 138 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2011 | 693 | 0.020 |
Why?
|
| Probability | 1 | 2010 | 306 | 0.020 |
Why?
|
| Picrates | 1 | 2008 | 5 | 0.020 |
Why?
|
| Spectrophotometry, Infrared | 1 | 2008 | 54 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2010 | 132 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2010 | 451 | 0.020 |
Why?
|
| Interferons | 1 | 2010 | 194 | 0.020 |
Why?
|
| Biphenyl Compounds | 1 | 2008 | 60 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2010 | 317 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2010 | 372 | 0.020 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2010 | 642 | 0.020 |
Why?
|
| Cattle | 1 | 2010 | 977 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 1202 | 0.020 |
Why?
|
| Base Sequence | 1 | 2011 | 2141 | 0.020 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2006 | 84 | 0.020 |
Why?
|
| Excipients | 1 | 2006 | 52 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2015 | 1218 | 0.020 |
Why?
|
| Apoptosis Inducing Factor | 1 | 2006 | 4 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2006 | 111 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2006 | 107 | 0.020 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2006 | 32 | 0.020 |
Why?
|
| Chemical Fractionation | 1 | 2006 | 30 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 2281 | 0.020 |
Why?
|
| Phosphatidylcholines | 1 | 2006 | 146 | 0.020 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2005 | 24 | 0.020 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2005 | 43 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2006 | 198 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 2005 | 162 | 0.010 |
Why?
|
| Densitometry | 1 | 2003 | 34 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2006 | 575 | 0.010 |
Why?
|
| Src Homology 2 Domain-Containing, Transforming Protein 1 | 1 | 2003 | 12 | 0.010 |
Why?
|
| Shc Signaling Adaptor Proteins | 1 | 2003 | 12 | 0.010 |
Why?
|
| Cell-Free System | 1 | 2003 | 48 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 2003 | 49 | 0.010 |
Why?
|
| Anthracenes | 1 | 2003 | 31 | 0.010 |
Why?
|
| Mifepristone | 1 | 2002 | 63 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 2005 | 309 | 0.010 |
Why?
|
| Oligonucleotides | 1 | 2003 | 140 | 0.010 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2002 | 66 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2002 | 171 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 4886 | 0.010 |
Why?
|
| Aged | 1 | 2010 | 22030 | 0.010 |
Why?
|
| Middle Aged | 1 | 2010 | 31075 | 0.000 |
Why?
|